The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study

Background: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5 cohorts) as well as by gestational age at birth in Japan. Methods: The JMDC database was used to retrospectively identif...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:ClinicoEconomics and outcomes research Ročník 14; s. 699 - 714
Hlavní autori: Chirikov, Viktor, Botteman, Marc, Simões, Eric AF
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Macclesfield Dove Medical Press Limited 01.01.2022
Taylor & Francis Ltd
Dove
Dove Medical Press
Predmet:
ISSN:1178-6981, 1178-6981
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Background: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5 cohorts) as well as by gestational age at birth in Japan. Methods: The JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3-5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 [yen] JPY) over 36-months of follow-up since index. Results: Healthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term ([yen] 277,727); Year 2 preterm ([yen] 530,302), late preterm ([yen] 270,797), full-term ([yen] 238,832); Years 3-5 preterm ([yen] 110,057), late preterm ([yen] 486,670), full-term ([yen] 289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory- and asthma/ wheezing-related attributable costs were substantially higher for RSV. Conclusion: RSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently. Keywords: respiratory syncytial virus, long-term follow-up, lower respiratory tract infection, prematurity
AbstractList Viktor Chirikov,1 Marc Botteman,1 Eric AF Simões2 1OPEN Health, Evidence & Access, Bethesda, MD, USA; 2Department of Pediatrics, University of Colorado School of Medicine, Department of Epidemiology, Center for Global Health, Colorado School of Public Health, and Section of Infectious Disease, Children’s Hospital Colorado, Aurora, CO, USACorrespondence: Viktor Chirikov, OPEN Health Evidence & Access, Bethesda, MD, 20814, USA, Tel +1 240 821 9662, Email ViktorChirikov@openhealthgroup.comBackground: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3– 5 cohorts) as well as by gestational age at birth in Japan.Methods: The JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3– 5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 ¥JPY) over 36-months of follow-up since index.Results: Healthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term (¥ 277,727); Year 2 preterm (¥ 530,302), late preterm (¥ 270,797), full-term (¥ 238,832); Years 3– 5 preterm (¥ 110,057), late preterm (¥ 486,670), full-term (¥ 289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory- and asthma/wheezing-related attributable costs were substantially higher for RSV.Conclusion: RSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently.Keywords: respiratory syncytial virus, long-term follow-up, lower respiratory tract infection, prematurity
Background: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5 cohorts) as well as by gestational age at birth in Japan. Methods: The JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3-5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 [yen] JPY) over 36-months of follow-up since index. Results: Healthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term ([yen] 277,727); Year 2 preterm ([yen] 530,302), late preterm ([yen] 270,797), full-term ([yen] 238,832); Years 3-5 preterm ([yen] 110,057), late preterm ([yen] 486,670), full-term ([yen] 289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory- and asthma/ wheezing-related attributable costs were substantially higher for RSV. Conclusion: RSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently. Keywords: respiratory syncytial virus, long-term follow-up, lower respiratory tract infection, prematurity
Background: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3– 5 cohorts) as well as by gestational age at birth in Japan. Methods: The JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3– 5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 ¥JPY) over 36-months of follow-up since index. Results: Healthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term (¥ 277,727); Year 2 preterm (¥ 530,302), late preterm (¥ 270,797), full-term (¥ 238,832); Years 3– 5 preterm (¥ 110,057), late preterm (¥ 486,670), full-term (¥ 289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory- and asthma/wheezing-related attributable costs were substantially higher for RSV. Conclusion: RSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently.
The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5 cohorts) as well as by gestational age at birth in Japan.BackgroundThe objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5 cohorts) as well as by gestational age at birth in Japan.The JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3-5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 ¥JPY) over 36-months of follow-up since index.MethodsThe JMDC database was used to retrospectively identify RSV and control patients between February 1, 2011 and January 31, 2016 and follow them through December 31, 2017. Infants with RSV infection (n = 9028 in Year 1; n = 4929 in Year 2; n = 2004 in Years 3-5) were matched to controls (n = 17,886; n = 9351; n = 3655, respectively) based on gestational age and year and quarter of birth; controls were assigned the index date (ie, diagnosis) of their respective match. Covariate-balancing propensity score weights were employed adjusting for remaining imbalances between cohorts. The main outcomes were average cumulative rates for all-cause, asthma/wheezing, and respiratory-related hospitalizations, physician and urgent care/emergency visits and associated costs (reported as 2018 ¥JPY) over 36-months of follow-up since index.Healthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term (¥277,727); Year 2 preterm (¥530,302), late preterm (¥270,797), full-term (¥238,832); Years 3-5 preterm (¥110,057), late preterm (¥486,670), full-term (¥289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory- and asthma/wheezing-related attributable costs were substantially higher for RSV.ResultsHealthcare utilization was significantly higher among RSV cases for most comparisons. All-cause average differential cost burden was higher for RSV, compared to controls, among the following cohorts: Year 1 full-term (¥277,727); Year 2 preterm (¥530,302), late preterm (¥270,797), full-term (¥238,832); Years 3-5 preterm (¥110,057), late preterm (¥486,670), full-term (¥289,986). While all-cause costs were similar for preterm and late preterm children in the Year 1 cohort, respiratory- and asthma/wheezing-related attributable costs were substantially higher for RSV.RSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently.ConclusionRSV infection had a significant long-term health and economic burden among children infected during their first year of life and later in life. Study findings have import for prevention strategies, currently directed at maternal immunization and monoclonal antibodies for preventing primary RSV infections in the first six months of life and beyond but also for older age not targeted currently.
Audience Academic
Author Botteman, Marc
Simões, Eric AF
Chirikov, Viktor
Author_xml – sequence: 1
  givenname: Viktor
  surname: Chirikov
  fullname: Chirikov, Viktor
– sequence: 2
  givenname: Marc
  surname: Botteman
  fullname: Botteman, Marc
– sequence: 3
  givenname: Eric AF
  surname: Simões
  fullname: Simões, Eric AF
BookMark eNptkt2KEzEUxwdZwXXdOx8gIIgXtk4mmY94IaylupXKyrYKXoVM5qSTZZrUJCPUN_DOh_DJfBIzbdHtsslFwjm_8z_5-D9OTow1kCRPcTrOMC1fTaZX1-MFqTLK8gfJKcZlNSpYhU9u7R8l597fpHFQRrKKnSa_li2guTWr0RLcGl2C6EIrhQP0OehO_xBBW4OEadBUWmPXWqK3vWvAIKvQ9eILmhkFcgdpgyat7hoXk39-_s7RVxDOD-EPYiPMa_TJ2Q0Yr8MWLaSNLT6KIFto0MS21gW0CH2zfZI8VKLzcH5Yz5Llu-lycjmaX72fTS7mI5nnJIxoljNVY0qwIlATRXIq6pLWVamUkKoqZJ6SrGQ1AJOFAJkp2mSCMcIkizVnyWwv21hxwzdOr4Xbcis03wWsW3HhgpYdcIUZYKUaJUtMU0gFkZKSBmRV4RyEjFpv9lqbvl5DI8EEJ7oj0eOM0S1f2e-cFXlBaBEFXhwEnP3Wgw98rb2ErhMGbO95VpKSFrTKcESf3UFvbO9MfKmBKljBGGb_qZWIF9BG2dhXDqL8oiQpKQtaDNT4HirOBuI_R3cpHeNHBc9vFbQ7r3jb9cP3-2Pw5R6UznrvQP17DJzywa18cCs_uDXi2R1c6rBzXjyQ7u4v-guMDvAT
CitedBy_id crossref_primary_10_1093_infdis_jiad367
crossref_primary_10_1186_s12889_025_23636_w
crossref_primary_10_3390_tropicalmed10080223
crossref_primary_10_1111_irv_70046
crossref_primary_10_1111_ped_70050
crossref_primary_10_1136_bmjph_2024_000975
crossref_primary_10_1016_j_arbres_2023_06_006
Cites_doi 10.1001/jama.2018.1150
10.1016/j.vaccine.2012.11.009
10.1056/NEJMoa0804877
10.1017/S0950268821000340
10.1111/ped.14957
10.1164/rccm.201609-1812OC
10.3389/fpubh.2019.00039
10.1186/s13643-020-01527-y
10.1002/cncr.27638
10.1073/pnas.1106536108
10.1001/archpedi.1986.02140200053026
10.1093/infdis/jiz161
10.3111/13696998.2011.578188
10.1111/j.1399-3038.2005.00298.x
10.1126/scitranslmed.aaj1928
10.1111/1475-6773.12090
10.1016/j.smim.2013.04.011
10.1016/S2213-2600(17)30303-X
10.3389/fimmu.2018.00226
10.2188/jea.JE20090066
10.1111/rssb.12027
10.1542/peds.2006-0907
10.7883/yoken.JJID.2017.261
10.1136/thx.2009.121582
10.1002/pds.3407
10.1080/13696998.2019.1658592
10.1056/NEJMoa1913556
10.1080/00273171.2011.540480
10.1016/S0140-6736(17)30938-8
10.1016/S1473-3099(18)30292-5
10.3201/eid2711.211565
10.1007/978-3-642-38919-1_2
10.1007/s40121-017-0151-4
10.1001/jamapediatrics.2013.2636
10.1186/s12992-019-0524-4
10.1016/S0140-6736(10)60206-1
10.1016/j.jval.2012.03.1388
10.1093/infdis/jiz278
10.2105/AJPH.2011.300398
10.1097/MD.0000000000011491
10.1093/infdis/jiz160
10.1056/NEJMoa1908380
10.3390/v12050505
ContentType Journal Article
Copyright COPYRIGHT 2022 Dove Medical Press Limited
2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 Chirikov et al.
2022 Chirikov et al. 2022 Chirikov et al.
Copyright_xml – notice: COPYRIGHT 2022 Dove Medical Press Limited
– notice: 2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 Chirikov et al.
– notice: 2022 Chirikov et al. 2022 Chirikov et al.
DBID AAYXX
CITATION
3V.
7XB
8C1
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.2147/CEOR.S382495
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Public Health Database
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central
One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
ProQuest Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Sustainability
Health Research Premium Collection
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Public Health
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Health Research Premium Collection (Alumni)
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
DocumentTitleAlternate Chirikov et al
EISSN 1178-6981
EndPage 714
ExternalDocumentID oai_doaj_org_article_f19e1ffdfc7140e0a3cc43dec8815eac
PMC9656346
A730376469
10_2147_CEOR_S382495
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: ;
GroupedDBID ---
0YH
53G
5VS
8C1
8G5
AAYXX
ABUWG
ADBBV
ADRAZ
AEUYN
AFFHD
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQTUD
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
M2O
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
RIG
RPM
TDBHL
UKHRP
VDV
ALIPV
3V.
7XB
8FK
COVID
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c553t-4259fb1431f3eb3f354ab74b87ffacf86c503279bee9c6aec2f4d2a9939c91f3
IEDL.DBID DOA
ISICitedReferencesCount 7
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000884753800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1178-6981
IngestDate Tue Oct 14 18:59:42 EDT 2025
Tue Nov 04 02:10:25 EST 2025
Sun Aug 24 04:02:26 EDT 2025
Sat Jul 26 03:18:56 EDT 2025
Tue Nov 11 10:07:11 EST 2025
Tue Nov 04 17:40:44 EST 2025
Thu May 22 21:32:59 EDT 2025
Tue Nov 18 22:34:30 EST 2025
Sat Nov 29 06:39:17 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License https://creativecommons.org/licenses/by-nc/3.0
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c553t-4259fb1431f3eb3f354ab74b87ffacf86c503279bee9c6aec2f4d2a9939c91f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/f19e1ffdfc7140e0a3cc43dec8815eac
PQID 2736969919
PQPubID 3933177
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_f19e1ffdfc7140e0a3cc43dec8815eac
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9656346
proquest_miscellaneous_2737464821
proquest_journals_2736969919
gale_infotracmisc_A730376469
gale_infotracacademiconefile_A730376469
gale_healthsolutions_A730376469
crossref_primary_10_2147_CEOR_S382495
crossref_citationtrail_10_2147_CEOR_S382495
PublicationCentury 2000
PublicationDate 2022-01-01
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Macclesfield
PublicationPlace_xml – name: Macclesfield
PublicationTitle ClinicoEconomics and outcomes research
PublicationYear 2022
Publisher Dove Medical Press Limited
Taylor & Francis Ltd
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Taylor & Francis Ltd
– name: Dove
– name: Dove Medical Press
References Sigurs (ref18) 2010; 65
Austin (ref25) 2011; 46
Miyama (ref22) 2021; 149
Griffiths (ref27) 2012; 15
Griffin (ref32) 2020; 383
Karron (ref44) 2018; 6
Malinczak (ref41) 2020; 12
Shi (ref2) 2017; 390
Madhi (ref33) 2020; 383
Anderson (ref38) 2013; 25
Li (ref24) 2013; 22
Ikegami (ref31) 2019; 15
Stensballe (ref42) 2006; 118
Swanson (ref36) 2011; 108
Nair (ref8) 2010; 375
Fonseca (ref3) 2018; 9
Goto (ref14) 2016; 48
Ledbetter (ref15) 2020; 23
Piedra (ref1) 2020; 221
Winterstein (ref23) 2013; 167
Ujiie (ref12) 2021; 27
Griffiths (ref28) 2012; 118
Glenn (ref37) 2013; 31
Kanou (ref11) 2018; 71
Quinn (ref34) 2020; 9
Sruamsiri (ref13) 2018; 97
Hall (ref4) 2009; 360
Kimura (ref19) 2010; 20
Hall (ref7) 2013; 372
Mochizuki (ref35) 2017; 196
Imai (ref26) 2014; 76
Yamagami (ref21) 2019; 7
Papanicolas (ref43) 2018; 319
Fauroux (ref5) 2017; 6
Glezen (ref6) 1986; 140
Shi (ref16) 2011; 14
Kobayashi (ref20) 2021; 64
Bell (ref30) 2012; 102
Henderson (ref17) 2005; 16
Zhu (ref40) 2017; 9
DuGoff (ref29) 2014; 49
Simões (ref9) 2020; 221
Chirikov (ref10) 2020; 221
Mazur (ref39) 2018; 18
References_xml – volume: 319
  start-page: 1024
  year: 2018
  ident: ref43
  publication-title: JAMA
  doi: 10.1001/jama.2018.1150
– volume: 31
  start-page: 524
  year: 2013
  ident: ref37
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.11.009
– volume: 360
  start-page: 588
  year: 2009
  ident: ref4
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0804877
– volume: 149
  year: 2021
  ident: ref22
  publication-title: Epidemiol Infect
  doi: 10.1017/S0950268821000340
– volume: 64
  start-page: e14957
  year: 2021
  ident: ref20
  publication-title: Pediatr Int
  doi: 10.1111/ped.14957
– volume: 196
  start-page: 29
  year: 2017
  ident: ref35
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201609-1812OC
– volume: 7
  start-page: 39
  year: 2019
  ident: ref21
  publication-title: Public Health Front
  doi: 10.3389/fpubh.2019.00039
– volume: 9
  start-page: 269
  year: 2020
  ident: ref34
  publication-title: Syst Rev
  doi: 10.1186/s13643-020-01527-y
– volume: 118
  start-page: 6079
  year: 2012
  ident: ref28
  publication-title: Cancer
  doi: 10.1002/cncr.27638
– volume: 108
  start-page: 9619
  year: 2011
  ident: ref36
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1106536108
– volume: 140
  start-page: 543
  year: 1986
  ident: ref6
  publication-title: Arch Pediatr Adolesc Med
  doi: 10.1001/archpedi.1986.02140200053026
– volume: 221
  start-page: 1205
  year: 2020
  ident: ref1
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiz161
– volume: 14
  start-page: 335
  year: 2011
  ident: ref16
  publication-title: J Med Econ
  doi: 10.3111/13696998.2011.578188
– volume: 16
  start-page: 386
  year: 2005
  ident: ref17
  publication-title: Pediatr Allergy Immunol
  doi: 10.1111/j.1399-3038.2005.00298.x
– volume: 9
  start-page: eaaj1928
  year: 2017
  ident: ref40
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aaj1928
– volume: 49
  start-page: 284
  year: 2014
  ident: ref29
  publication-title: Health Serv Res
  doi: 10.1111/1475-6773.12090
– volume: 25
  start-page: 160
  year: 2013
  ident: ref38
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2013.04.011
– volume: 6
  start-page: 65
  year: 2018
  ident: ref44
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(17)30303-X
– volume: 9
  start-page: 226
  year: 2018
  ident: ref3
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.00226
– volume: 20
  start-page: 413
  year: 2010
  ident: ref19
  publication-title: J Epidemiol
  doi: 10.2188/jea.JE20090066
– volume: 76
  start-page: 243
  year: 2014
  ident: ref26
  publication-title: J R Stat Soc Series B Stat Methodol
  doi: 10.1111/rssb.12027
– volume: 118
  start-page: E1360
  year: 2006
  ident: ref42
  publication-title: Pediatrics
  doi: 10.1542/peds.2006-0907
– volume: 71
  start-page: 250
  year: 2018
  ident: ref11
  publication-title: Jpn J Infect Dis
  doi: 10.7883/yoken.JJID.2017.261
– volume: 65
  start-page: 1045
  year: 2010
  ident: ref18
  publication-title: Thorax
  doi: 10.1136/thx.2009.121582
– volume: 22
  start-page: 524
  year: 2013
  ident: ref24
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.3407
– volume: 23
  start-page: 139
  year: 2020
  ident: ref15
  publication-title: J Med Econ
  doi: 10.1080/13696998.2019.1658592
– volume: 383
  start-page: 415
  year: 2020
  ident: ref32
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1913556
– volume: 46
  start-page: 119
  year: 2011
  ident: ref25
  publication-title: Multivariate Behav Res
  doi: 10.1080/00273171.2011.540480
– volume: 390
  start-page: 946
  year: 2017
  ident: ref2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)30938-8
– volume: 18
  start-page: e295
  year: 2018
  ident: ref39
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30292-5
– volume: 27
  start-page: 11
  year: 2021
  ident: ref12
  publication-title: Emerg Infect Dis
  doi: 10.3201/eid2711.211565
– volume: 372
  start-page: 39
  year: 2013
  ident: ref7
  publication-title: Curr Top Microbiol Immunol
  doi: 10.1007/978-3-642-38919-1_2
– volume: 48
  start-page: PA1324
  year: 2016
  ident: ref14
  publication-title: Eur Respir J
– volume: 6
  start-page: 173
  year: 2017
  ident: ref5
  publication-title: Infect Dis Ther
  doi: 10.1007/s40121-017-0151-4
– volume: 167
  start-page: 1118
  year: 2013
  ident: ref23
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2013.2636
– volume: 15
  start-page: 1
  year: 2019
  ident: ref31
  publication-title: Global Health
  doi: 10.1186/s12992-019-0524-4
– volume: 375
  start-page: 1545
  year: 2010
  ident: ref8
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60206-1
– volume: 15
  start-page: 656
  year: 2012
  ident: ref27
  publication-title: Value Health
  doi: 10.1016/j.jval.2012.03.1388
– volume: 221
  start-page: 1256
  year: 2020
  ident: ref9
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiz278
– volume: 102
  start-page: 1399
  year: 2012
  ident: ref30
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.2011.300398
– volume: 97
  start-page: e11491
  year: 2018
  ident: ref13
  publication-title: Medicine
  doi: 10.1097/MD.0000000000011491
– volume: 221
  start-page: 1244
  year: 2020
  ident: ref10
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiz160
– volume: 383
  start-page: 426
  year: 2020
  ident: ref33
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1908380
– volume: 12
  start-page: 5
  year: 2020
  ident: ref41
  publication-title: Viruses
  doi: 10.3390/v12050505
SSID ssj0000493289
Score 2.2575448
Snippet Background: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1,...
The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and...
Viktor Chirikov,1 Marc Botteman,1 Eric AF Simões2 1OPEN Health, Evidence & Access, Bethesda, MD, USA; 2Department of Pediatrics, University of Colorado School...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 699
SubjectTerms Age groups
Analysis
Asthma
Codes
Cohort analysis
Economic aspects
Estimates
Gestational age
Health aspects
Health care
Health care expenditures
Health services utilization
Hospitalization
Immunization
Infection
Infections
long-term follow-up
lower respiratory tract infection
Medical care
Medical economics
Original Research
Palivizumab
Pandemics
Patients
prematurity
Respiratory syncytial virus
Respiratory tract diseases
Utilization
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELagywEJ8UYEFjASiAMK28R2YnNBu1VXgJZStQUtpyjxY7fSylnaLhI_gRs_gl_GL2EmcQsBwYWrPVYcefzNw_Mg5FFZplViXBZbo0XMk76MK6ZMLETqElVKK6qma8lBPhrJw0M1Dg63ZQirXGNiA9Sm1ugj3wExm6kMtBn14vRjjF2j8HU1tNA4T7awUhnvka294Wg82XhZQP9lYFK0Ee_YkmdnMHw7eTZlEnsud2RRU7L_T2D-PVjyF-mzf-V_932VXA56J91tGeUaOWf9dXKpddrRNhfpBvkKTEMPan8UzwCwwzDGhtF3q_lJyNikpTd0nc9M2zQIWjs6mb6nr0Jol6dzTwchT5x-__JN0A9wpZY4_BrEs39Ox_gK4DEihE6xlCZ9UyIDGTqoj8EkoBjg-Pkmme0PZ4OXcWjZEGsh2CoGBFCuAh0scQzMdMcEL6ucVzJ3rtROZlr0WZqrylqls9Lq1HGTlqAkKa1gzS3S87W3twkVwhhVpZj6KjmoeUowJZ3lGeiMAFM8Ik_XZ1foUM4cu2qcFGDW4EkXeNJFOOmIPN5Qn7ZlPP5Ct4dssKHB4tvNQL04KsJdLoCJbeKccRqrHdp-ybTmzFgtZSJAkEXkATJR0WaybiCk2AU0BTznmYrIk4YCQQQ2rcuQCwG_juW4OpTbHUq4_Lo7vea6IoDPsvjJchF5uJnGlRhQ52191tDkPOMyTSKSdxi88-_dGT8_bgqQKzACGM_u_Pvjd8nFFHNFGn_VNumtFmf2HrmgP63my8X9cFN_AOsYS3E
  priority: 102
  providerName: ProQuest
Title The Long-Term Healthcare Utilization and Economic Burden of RSV Infection in Children ≤5 Years in Japan: Propensity Score Matched Cohort Study
URI https://www.proquest.com/docview/2736969919
https://www.proquest.com/docview/2737464821
https://pubmed.ncbi.nlm.nih.gov/PMC9656346
https://doaj.org/article/f19e1ffdfc7140e0a3cc43dec8815eac
Volume 14
WOSCitedRecordID wos000884753800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: DOA
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources (ISSN International Center)
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: M~E
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: 8C1
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library (ProQuest)
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: M2O
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVAWR
  databaseName: Taylor & Francis Open Access (WRLC)
  customDbUrl:
  eissn: 1178-6981
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493289
  issn: 1178-6981
  databaseCode: 0YH
  dateStart: 20091201
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELZg4YCEEL8isBQjgTigsHVsJza33aorFm27VVtQ9xQ5js0WrVK07SLxCNx4CJ6MJ2EmcasGhLhwycEeS45n_PmzNT-EPDcmKVjp09iVVsaCdVVccF3GUiaeaaOcLOqqJcfZcKhmMz3aKvWFPmFNeuBm4fZghGPel95iajnXNdxawUtnlWISUAPRF1jP1mXqU8N7eVLXv2MMrkmpVqzxeseyPHu9_sn49YQrrLvcOo_qtP1_gvPvDpNbJ9DhbXIrUEe630z5DrniqrvkZvPuRptwonvkO-idHi-qj_EUMDc0o3sXfb-an4egS2qqkq5DkmkTyUAXno4nH-hR8M6q6LyivRDqTX9--yHpKeyKJTa_gxO2ekNH-JBfoVMHnWA2TDowaAMl7S3OgNVT9FH8ep9MD_vT3ts4VF2IrZR8FcMm1r4AGsU8h5u251KYIhOFyrw31qvUyi5PMl04p21qnE28KBMDPEdbDWMekJ1qUbmHhEpZlrpIMHpVCWBqWnKtvBMp0D5AGhGRV-ulz23ISI6FMc5zuJmgonJUVB4UFZEXG-nPTSaOv8gdoBY3Mpg_u24Aq8qDVeX_sqqIPEUbyJtg1A0K5PsAiADJItUReVlLIA7ApK0J4Qzw65hRqyW525KE_Wvb3Ws7ywN-LHMglalOgbtD97NNN45En7jKLS5rmUykQiUsIlnLPlv_3u6p5md1DnENPJ6L9NH_WKzH5EaCQSH1w9Qu2VldXLon5Lr9spovLzrkajZT8FU91iHXDvrD0bhTb1b4DpITaBsdDUanvwDcWUWR
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3dbtMwFLZGhwQS4h8RGMxITFygsCaxExsJoVE2rawd1VrQdmUljr1VmpLRdqA9Anc8BLe8FE_COYlbCAjudsGtffLj5Pza5zuHkMdpGmZBbmPf5Jr7LGgLP4tk7nMe2kCmwvCs6lrSS3Z3xf6-HCyRb3MsDKZVznVipajzUuMe-TqY2VjG4M3IlycffOwahaer8xYaNVvsmLNPELJNX3Rfw_9dC8OtzVFn23ddBXzNeTTzgUmlzcBNCGwEkaSNOEuzhGUisTbVVsSat6MwkZkxUsep0aFleZiCHZdawjVw2wtkmcFtRIssD7r9wcFiUwfc7QgimDrBHjsArXc23-49G0YCWzw3TF_VIeBPO_B7buYvxm7r2n_2ma6Tq86rphu1GNwgS6a4Sa7UW5K0RlrdIl9AJGivLA79EZgjN4yZb_TdbHzs8Kg0LXI6R2vTGuRBS0v3hu9p1yWuFXRc0I5DwdPvn79yegBLnuLwG3A-iud0gGccBea70CEWCqX9FMUjp53yCAIeiumbZ7fJ6Dy-yR3SKsrC3CWU8zyXWYjAXsHAiZU8ksIaFoNHDEqYeeTpnFWUdsXasWfIsYKgDRlLIWMpx1geWVtQn9RFSv5C9wq5bkGDpcWrgXJyqJymUiCiJrA2txprOZp2GmnNotxoIQIOZtojq8izqsbpLhSk2gBbAdaKxdIjTyoKVJHw0jp1SA9YOhYba1CuNChBtenm9JzJlVOtU_WTwz3yaDGNV2K6YGHK04omYTETYeCRpCFPjbU3Z4rxUVVeXUKIE7H43r8fvkoubY_6PdXr7u7cJ5dDRMVUO3MrpDWbnJoH5KL-OBtPJw-dkqBEnbO8_QBdwqmQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3dbtMwFLbGQAgJ8Y8IDGYkJi5QaJPYqY2E0OhWUVZKtXZoXFmJY2-VpmS0HWiPwB0PwUvwOjwJ5yROISC42wW39smPk-_82eeHkEdJEqZBZmPfZJr7LGgLP41k5nMe2kAmwvC07Foy6AyHYn9fjlbItzoXBsMqa5lYCuqs0LhH3gI1G8sYrBnZsi4sYrTVe3H8wccOUnjSWrfTqCCyY04_gfs2f97fgn-9EYa97Un3le86DPia82jhA2ClTcFkCGwEXqWNOEvSDktFx9pEWxFr3o7CjkyNkTpOjA4ty8IEdLrUEq6B254j5-HNIowmE91gub0DhncEvkwVao-9gFrd7be7T8eRwGbPDSVY9gr4UyP8HqX5i9rrXf2PP9g1csXZ2nSzYo7rZMXkN8jlaqOSVvlXN8kXYBQ6KPIDfwJKyg1jPBzdW0yPXJYqTfKM1jnctEr9oIWlu-N3tO_C2XI6zWnX5cbT75-_cvoeljzH4ddgkuTP6AhPPnKMgqFjLB9K3yTINBntFofgBlEM6jy9RSZn8U1uk9W8yM0dQjnPMpmGmO4rGJi2kkdSWMNisJNBNDOPPKlho7Qr4Y6dRI4UuHIIMoUgUw5kHtlYUh9XpUv-QvcSEbikwYLj5UAxO1BOfilgXBNYm1mNFR5NO4m0ZlFmtBABB-XtkXXEr6qyd5diU22CBgEdxmLpkcclBQpOeGmduPwPWDqWIGtQrjUoQeDp5nQNeOUE7lz9RLtHHi6n8UoMIsxNcVLSdFjMRBh4pNPgrcbamzP59LAsui7B8YlYfPffD18nF4HJ1KA_3LlHLoWYKlNu162R1cXsxNwnF_THxXQ-e1BKC0rUGTPbD6A3sIg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Long-Term+Healthcare+Utilization+and+Economic+Burden+of+RSV+Infection+in+Children+%E2%89%A45+Years+in+Japan%3A+Propensity+Score+Matched+Cohort+Study&rft.jtitle=ClinicoEconomics+and+outcomes+research&rft.au=Chirikov%2C+Viktor&rft.au=Botteman%2C+Marc&rft.au=Sim%C3%B5es%2C+Eric+AF&rft.date=2022-01-01&rft.issn=1178-6981&rft.eissn=1178-6981&rft.volume=14&rft.spage=699&rft.epage=714&rft_id=info:doi/10.2147%2FCEOR.S382495&rft.externalDBID=n%2Fa&rft.externalDocID=10_2147_CEOR_S382495
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6981&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6981&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6981&client=summon